Australia - English - Department of Health (Therapeutic Goods Administration)

amgen australia pty ltd - darbepoetin alfa, quantity: 200 microgram/ml - injection, solution - excipient ingredients: dibasic sodium phosphate; monobasic sodium phosphate monohydrate; sodium chloride; polysorbate 80; water for injections - aranesp is indicated for the treatment of anaemia associated with chronic renal failure (crf). aranesp is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignacies where anaemia develops as a result of concommitantly administered chemotherapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

amgen australia pty ltd - darbepoetin alfa, quantity: 25 microgram/ml - injection, solution - excipient ingredients: monobasic sodium phosphate monohydrate; polysorbate 80; water for injections; sodium chloride; dibasic sodium phosphate - aranesp is indicated for the treatment of anaemia associated with chronic renal failure (crf). aranesp is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignacies where anaemia develops as a result of concommitantly administered chemotherapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

amgen australia pty ltd - darbepoetin alfa, quantity: 100 microgram/ml - injection, solution - excipient ingredients: sodium chloride; dibasic sodium phosphate; monobasic sodium phosphate monohydrate; water for injections; polysorbate 80 - aranesp is indicated for the treatment of anaemia associated with chronic renal failure (crf). aranesp is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignacies where anaemia develops as a result of concommitantly administered chemotherapy.

Israel - English - Ministry of Health

roche pharmaceuticals (israel) ltd - methoxy polyethylene glycol-epoetin beta - solution for injection - methoxy polyethylene glycol-epoetin beta 360 mcg / 0.6 ml - erythropoietin - erythropoietin - treatment of anemia associated with chronic kidney disease (ckd).

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - epoetin lambda, quantity: 5000 iu - injection, solution - excipient ingredients: sodium hydroxide; dilute hydrochloric acid; water for injections; monobasic sodium phosphate dihydrate; polysorbate 80; sodium chloride; glycine; dibasic sodium phosphate dihydrate - treatment of patients with symptomatic or transfusion requiring anaemia associated with chronic renal failure to improve their quality of life by improving energy levels, exercise performance, fatigue and sleep patterns and by reducing the need for blood transfusions.. treatment of anaemia in patients with nonmyeloid malignancies where anaemia develops as a result of concomitantly administered chemotherapy, and where blood transfusion is not considered appropriate. adult patients with mild to moderate anaemia (haemoglobin > 100 to less than or equal to 130g/l) scheduled for elective surgery with an expected moderate blood loss (two to four units or 900 to 1,800ml) to reduce exposure to allogeneic blood transfusion and to facilitate erythropoietic recovery.. augment autologous blood collection and to limit the decline in haemoglobin in anaemic adult patients who are scheduled for major elective surgery and who are not expected to predeposit their complete perioperative blood needs.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - epoetin lambda, quantity: 3000 iu - injection, solution - excipient ingredients: polysorbate 80; monobasic sodium phosphate dihydrate; water for injections; glycine; dilute hydrochloric acid; sodium chloride; sodium hydroxide; dibasic sodium phosphate dihydrate - treatment of patients with symptomatic or transfusion requiring anaemia associated with chronic renal failure to improve their quality of life by improving energy levels, exercise performance, fatigue and sleep patterns and by reducing the need for blood transfusions.. treatment of anaemia in patients with nonmyeloid malignancies where anaemia develops as a result of concomitantly administered chemotherapy, and where blood transfusion is not considered appropriate. adult patients with mild to moderate anaemia (haemoglobin > 100 to less than or equal to 130g/l) scheduled for elective surgery with an expected moderate blood loss (two to four units or 900 to 1,800ml) to reduce exposure to allogeneic blood transfusion and to facilitate erythropoietic recovery.. augment autologous blood collection and to limit the decline in haemoglobin in anaemic adult patients who are scheduled for major elective surgery and who are not expected to predeposit their complete perioperative blood needs.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - epoetin lambda, quantity: 1000 iu - injection, solution - excipient ingredients: sodium hydroxide; water for injections; dibasic sodium phosphate dihydrate; polysorbate 80; dilute hydrochloric acid; monobasic sodium phosphate dihydrate; glycine; sodium chloride - treatment of patients with symptomatic or transfusion requiring anaemia associated with chronic renal failure to improve their quality of life by improving energy levels, exercise performance, fatigue and sleep patterns and by reducing the need for blood transfusions.. treatment of anaemia in patients with nonmyeloid malignancies, where anaemia develops as a result of concomitantly administered chemotherapy, and where blood transfusion is not considered appropriate. adult patients with mild to moderate anaemia (haemoglobin > 100 to less than or equal to 130g/l) scheduled for elective surgery with an expected moderate blood loss (two to four units or 900 to 1,800ml) to reduce exposure to allogeneic blood transfusion and to facilitate erythropoietic recovery.. augment autologous blood collection and to limit the decline in haemoglobin in anaemic adult patients who are scheduled for major elective surgery and who are not expected to predeposit their complete perioperative blood needs.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - epoetin lambda, quantity: 6000 iu - injection, solution - excipient ingredients: monobasic sodium phosphate dihydrate; dibasic sodium phosphate dihydrate; polysorbate 80; dilute hydrochloric acid; water for injections; sodium hydroxide; glycine; sodium chloride - treatment of patients with symptomatic or transfusion requiring anaemia associated with chronic renal failure to improve their quality of life by improving energy levels, exercise performance, fatigue and sleep patterns and by reducing the need for blood transfusions.. treatment of anaemia in patients with nonmyeloid malignancies where anaemia develops as a result of concomitantly administered chemotherapy, where blood transfusion is not considered appropriate. adult patients with mild to moderate anaemia (haemoglobin > 100 to less than or equal to 130g/l) scheduled for elective surgery with an expected moderate blood loss (two to four units or 900 to 1,800ml) to reduce exposure to allogeneic blood transfusion and to facilitate erythropoietic recovery.. augment autologous blood collection and to limit the decline in haemoglobin in anaemic adult patients who are scheduled for major elective surgery and who are not expected to predeposit their complete perioperative blood needs.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - epoetin lambda, quantity: 4000 iu - injection, solution - excipient ingredients: water for injections; sodium chloride; glycine; polysorbate 80; dilute hydrochloric acid; sodium hydroxide; monobasic sodium phosphate dihydrate; dibasic sodium phosphate dihydrate - treatment of patients with symptomatic or transfusion requiring anaemia associated with chronic renal failure to improve their quality of life by improving energy levels, exercise performance, fatigue and sleep patterns and by reducing the need for blood transfusions.. treatment of anaemia in patients with nonmyeloid malignancies where anaemia develops as a result of concomitantly administered chemotherapy, and where blood transfusion is not considered appropriate. adult patients with mild to moderate anaemia (haemoglobin > 100 to less than or equal to 130g/l) scheduled for elective surgery with an expected moderate blood loss (two to four units or 900 to 1,800ml) to reduce exposure to allogeneic blood transfusion and to facilitate erythropoietic recovery.. augment autologous blood collection and to limit the decline in haemoglobin in anaemic adult patients who are scheduled for major elective surgery and who are not expected to predeposit their complete perioperative blood needs.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - epoetin lambda, quantity: 10000 iu - injection, solution - excipient ingredients: sodium chloride; monobasic sodium phosphate dihydrate; dilute hydrochloric acid; glycine; dibasic sodium phosphate dihydrate; polysorbate 80; water for injections; sodium hydroxide - treatment of patients with symptomatic or transfusion requiring anaemia associated with chronic renal failure to improve their quality of life by improving energy levels, exercise performance, fatigue and sleep patterns and by reducing the need for blood transfusions.. treatment of anaemia in patients with nonmyeloid malignancies where anaemia develops as a result of concomitantly administered chemotherapy, and where blood transfusion is not considered appropriate. adult patients with mild to moderate anaemia (haemoglobin > 100 to less than or equal to 130g/l) scheduled for elective surgery with an expected moderate blood loss (two to four units or 900 to 1,800ml) to reduce exposure to allogeneic blood transfusion and to facilitate erythropoietic recovery.. augment autologous blood collection and to limit the decline in haemoglobin in anaemic adult patients who are scheduled for major elective surgery and who are not expected to predeposit their complete perioperative blood needs.